Jan-Peter WARNKE

Policy topics Jan-Peter WARNKE is active on

What Jan-Peter WARNKE has said (9)

• 2026-03-02 “Answer given by Ms Zaharieva on behalf of the European Commission 1.6.2026 Written question Under the Horizon Europe (HE) [1] legal framework, all funded actions must comply with ethical principles and applicable national, EU and international legislation [2] . At the level of HE implementation, several mechanisms are in place to prevent that EU funds are used for activities that could be unethical, or contrary to international or EU law. Applicants must complete an ethics self-assessment and all proposals considered for funding undergo an ethics review carried out by independent ethics experts [3] . Furthermore, for Israeli entities, specific eligibility criteria related to the place of establishment or activities apply [4] . Article 2(2) of the Agreement associating Israel to HE [5] sets out the principle that Israeli entities participate in the HE programme under terms and conditions equivalent to those applicable to legal entities established in the EU. Any actions of the State of Israel cannot be considered automatically attributable to Israeli entities participating in HE. The HE Agreement is based on the Euro-Mediterranean Association Agreement [6] . In the context of the events in Gaza, the Commission concluded that there are indications that Israel would be in breach of Article 2 of the Euro-Mediterranean Association Agreement. The Commission therefore proposed to the Council a suspension of trade-related provisions of the Association Agreement as well as a partial suspension of the application of the HE Agreement with Israel, so that legal entities established in Israel would not be eligible to participate in calls for grant and investment support under the HE European Innovation Council Accelerator. The Council has not taken a decision yet. The Commission continues to closely monitor the situation. [1] https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe_en. [2] Article 19(1) of Regulation (EU) 2021/695 (HE Regulation) explicitly requires that: ‘Actions carried out under the Programme shall comply with ethical principles and relevant Union, national and international law, including the Charter and the European Convention for the Protection of Human Rights and Fundamental Freedoms and its Supplementary Protocols’. These obligations are also embedded in the HE Model Grant Agreement, Article 14, and are applicable to all beneficiaries of EU funding under HE, see https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf. [3] The HE ethics appraisal scheme ensures a rigorous ethical evaluation. Proposals with serious or complex ethics issues must undergo an ethics assessment and may be made subject to specific ethics requirements which become obligations in the grant agreement as ‘ethics deliverables’. Furthermore, Article 19(3) of the HE Regulation in its first sentence sets out the systematic screening of the ongoing actions regarding the observance of the ethical standards under paragraph 1. Any ethical concerns arising during implementation of a project are taken very seriously and may lead to ethics-related checks or reviews when appropriate. A non-compliance may trigger contractual measures such as reduction of the EU funding or termination of the grant or termination of the participation of the respective beneficiary. [4] https://op.europa.eu/en/publication-detail/-/publication/044b0978-9f3f-4cdc-b0df-827d94af5c6c/language-en. [5] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:22022A0323(10). [6] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L:2000:147:FULL.”
  Relations with Israel - Palestine
• 2026-03-02 “Answer given by Ms Zaharieva on behalf of the European Commission 28.5.2026 Written question Nuclear activities that contribute to the achievement of the Treaty on the Functioning of the European Union (TFEU) [1] objectives can be funded under the TFEU where the Euratom Treaty [2] does not lay down exhaustive or specific rules. This is the case for the European Innovation Council (EIC). A s set out in Article 19(1) of the Horizon Europe (HE) Regulation [3] , any action carried out under the HE programme must comply with ethical principles and relevant EU, national and international law, including the EU Charter of Fundamental Rights [4] and the European Convention for the Protection of Human Rights and Fundamental Freedoms and its Supplementary Protocols [5] . Export control of dual use items in the EU [6] is based on a common list of dual-use items [7] that must be controlled in all Member States [8] . From the description of the AUTOFLY project coordinated by Sightec, there is no mention of nuclear materials or technologies being involved. Article 48(2) of the HE Regulation, as recently amended [9] , sets out the eligibility conditions and restrictions under the EIC Accelerator that apply for support for innovation in critical defence technologies and may be applied for support for applications with potential dual-use. Sightec applied successfully for EIC blended finance support in 2021 and received the grant support but was rejected for the equity investment [10] , so there is no ongoing investment in the company. Regarding the statement by Sightec’s CEO pointing to dual use, it should be noted that the HE legal base, at the time, specified that activities supported had to be exclusively civilian [11] . In addition, the European Defence Fund (EDF) has strict eligibility conditions for participation [12] . Israel is not associated to the EDF and it is therefore excluded from participation. [1] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX%3A12012E%2FTXT . [2] https://www.consilium.europa.eu/en/resources/publications/euratom-treaty/. [3] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02021R0695-20251224. [4] https://fra.europa.eu/en/eu-charter. [5] https://www.echr.coe.int/documents/d/echr/Convention_ENG. [6] Dual-Use Regulation 2021/821. [7] ‘EU control list’. [8] Any action that would not respect non-proliferation would be in clear violation of the above and appropriate measures would be taken. [9] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202502653. [10] I n line with the EIC Fund’s investment guidelines. [11] This does not exclude that subsequent developments of the technologies could have dual use. [12] As a general rule, participating entities must be established in the EU or an associated third country (currently Norway and soon Ukraine), have their executive management structures in the EU or an associated third country, and not be controlled by a non-associated third country.”
  EU competences on foreign affairs · EU competences on defence
• 2026-02-27 “Answer given by Ms Zaharieva on behalf of the European Commission 1.6.2026 Written question 1. Article 48(2) of the Horizon Europe Regulation, as recently amended [1] , sets out the eligibility conditions and restrictions under the European Innovation Council Accelerator that apply regarding support for innovation in critical defence technologies as well as regarding support for potential dual-use applications: — Regarding support for critical defence technologies, the participation is limited to legal entities established in the EU, in Ukraine or in a European Economic Area ( EEA ) member associated to Horizon Europe [2] . Therefore, legal entities established in Israel are not eligible to participate. — Regarding support for dual-use applications, the work programme may limit the participation to legal entities established in Member States or to legal entities established in specified associated countries in addition to Member States [3] . 2. In case the State of Israel would in future not respect its obligations under Article 2 of the Euro-Mediterranean Agreement [4] , the Commission has the prerogative to propose appropriate and proportionate measures , as it did in July 2025 [5] . In this respect, as the Council has not taken a decision yet on the Commission proposal to partially suspend the application of the Horizon Europe Association Agreement with Israel, the Agreement remains applicable in full . Any Horizon Europe action must comply with ethical principles and respect relevant EU, national and international law [6] . For Israeli entities, specific eligibility criteria related to the place of establishment or activities continue to apply [7] . [1] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202502653. [2] Furthermore, legal entities that are directly or indirectly controlled by a third country other than Ukraine or an EEA member associated to Horizon Europe (such as Israel), or by legal entities of such a third country, are excluded from participation unless a guarantee is provided that support for the legal entity would not contravene the security and defence interests of the EU and its Member States, as established in the framework of the common foreign and security policy pursuant to Title V of the Treaty on European Union, including respect for the principle of good neighbourly relations. The guarantees must be approved in accordance with the national procedures of the Member State or the EEA member associated to Horizon Europe in which the legal entity is established. [3] For duly justified and exceptional reasons, in order to guarantee the protection of the strategic interests of the EU and its Member States, the work programme may also exclude the participation of legal entities established in the EU or in associated countries directly or indirectly controlled by non-associated third countries or by legal entities of non-associated third countries from individual calls for proposals, or make their participation subject to conditions set out in the work programme. [4] Euro-Mediterranean Agreement establishing an association between the European Communities and their Member States, of the one part, and the State of Israel, of the other part https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02000A0621(01)-20130701. [5] COM(2025) 620 final, https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52025PC0620. [6] As per Article 19 of the Horizon Europe Regulation. [7] Guidelines on the eligibility of Israeli entities and their activities in the territories occupied by Israel since June 1967 for grants, prizes and financial instruments funded by the EU from 2014 onwards, OJ/C 205/05 of 19.07.2013, https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52013XC0719(03).”
  Relations with Israel - Palestine · EU competences on defence
• 2025-11-24 “E-004672/2025 Answer given by Ms Šuica on behalf of the European Commission As noted in the EU position for the 13 th EU-Israel Association Council 1 , the EU strongly condemns the demolitions of structures funded by the EU or its Member States and always expects that Israel makes good the damages in accordance with international law. The EU considers that political engagement and open dialogue are the most effective ways to convey EU concerns and will continue to reaffirm its commitment to the applicability of international human rights and humanitarian law in the occupied Palestinian territory, for a just and lasting peace based on the two-state solution. The EU is informed by its humanitarian partners about demolitions which directly impact EU funded humanitarian operations. The humanitarian partners file an incident report containing all relevant information. On 18 December 2025 the EU released the report ‘One Year Report on Demolitions and Seizures in the West Bank, including East Jerusalem’. In 2024, 83 EU-funded structures were demolished or seized, representing EUR 377 784 in financial losses 2 . The report on figures for the year 2025 will be released in 2026. In Gaza, a realistic estimation of damages on EU-funded infrastructures in Gaza can only take place once hostilities have fully ceased and full access is granted. The EU is conducting a final rapid damage and needs assessment in partnership with the UN and the World Bank. The assessment, to be published in early 2026, will provide a comprehensive overview of recovery needs per sector. 1 https://www.consilium.europa.eu/en/meetings/international-ministerial-meetings/2025/02/24/. 2 Figures regarding demolitions, settler violence, and abandonment remain underreported due to mobility and security constraints. Data may be subject to change at any time depending on new available data: https://www.eeas.europa.eu/sites/default/files/2025/documents/PALESTINE%20EU_annual%20demolitions%2 0report%201%20January%20%E2%80%93%2031%20December%202024%20%20Ares%282025%2911345216.pdf.”
  Relations with Israel - Palestine
• 2025-10-15 “E-004033/2025 Answer given by Ms Šuica on behalf of the European Commission Gaza must be rebuilt and Palestinians must be able to return and live in a safe environment where governance is legitimate and the economy is relaunched. The Commission will contribute and support all efforts towards a safe, sustainable and lasting peace, based on the two-state solution by mobilising the tools at its disposal and will continue providing humanitarian assistance and to support the early recovery and reconstruction of Gaza, when conditions are met. The EU strongly condemns the demolitions of structures funded by the EU or its Member States and expects Israel to make good the damage in accordance with international law. The EU, together with the UN and the World Bank, is finalising a Rapid Damage and Needs Assessment which will provide a comprehensive overview of losses until October 2025 ceasefire and recovery needs per sector 1 . The EU bilateral financial support to Israel remains suspended 2 . The Commission continues to support World Health Organisation with medical evacuations of paediatric patients from Gaza and Cairo to Europe under the Union Civil Protection Mechanism (UCPM) and, of the time of writing, 450 patients and 1240 companions have been evacuated with the support of 13 Member States (BE, DE, EL, ES, FR, IE, IT, LU, MT, NL, RO, SI, SK) and three UCPM participating states (AL, NO, TR). The Commission will continue to advocate to expand receiving capacity, while calling on all parties to facilitate safe and timely patient movements. Additionally, a joint statement signed by several Member States, international partners as well as the High Representative/Vice-President, the Commissioner for Mediterranean and the Commissioner for Equality, Preparedness and Crisis Management was issued in September 2025 3 , calling for the restoration of the medical corridor from Gaza to the occupied West Bank, including East Jerusalem. 1 Report expected to be published in 2026. 2 https://ec.europa.eu/commission/presscorner/detail/ov/SPEECH_25_2053. 3 https://via.ritzau.dk/pressemeddelelse/14593325/joint-statement-offer-to-assist-with-treatments-of-patientsfrom-gaza-in-the-occupied-west-bank-including-east-jerusalem?lang=en.”
  EU Development & Humanitarian Aid · Relations with Israel - Palestine
• 2025-07-09 “E-002807/2025 Answer given by Mr Várhelyi on behalf of the European Commission As mentioned in its reply to P-002033/25 1 , the Commission is working to address challenges identified regarding the regulatory framework for medical devices and in vitro diagnostics. It is conducting a targeted evaluation of the Regulations (EU) 2017/745 2 and (EU) 2017/746 3 which will be finalised in the fourth quarter of 2025 4 . Based on this evaluation, the Commission will, by the end of 2025, propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics, with a view to facilitate businesses’ operations across the EU single market, and effectively protecting patient safety and public health 5 . In the context of the targeted evaluation of the regulatory framework for medical devices, the Commission conducted a public consultation and call for evidence focused on identifying problems in the current legal framework. It is therefore well informed about the positions of various stakeholders, including representatives of industry, patients and healthcare professionals. The Commission also regularly discusses this matter with the European Parliament and Member States. Through an additional call for evidence, the Commission will gather input for addressing the identified problems by means of a targeted revision of the Regulations on medical devices. 1 https://www.europarl.europa.eu/doceo/document/P-10-2025-002033-ASW_EN.html. 2 http://data.europa.eu/eli/reg/2017/745/oj. 3 http://data.europa.eu/eli/reg/2017/746/oj. 4 See EU rules on medical devices and in vitro diagnostics – targeted evaluation. https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/14155-EU-rules-on-medical-devicesand-in-vitro-diagnostics-targeted-evaluation_en. 5 See Medical devices and in vitro diagnostics – targeted revision of EU rules: https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/14808-Medical-devices-and-in-vitrodiagnostics-targeted-revision-of-EU-rules_en; see also Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions, Choose Europe for life sciences: A strategy to position the EU as the world’s most attractive place for life sciences by 2030, COM(2025)525 final, 2.7.2025.”
  Medical devices
• 2025-01-15 “E-000157/2025 Answer given by President von der Leyen on behalf of the European Commission The report by Mario Draghi on the future of European competitiveness was prepared on initiative by the Commission, as indicated by the President in her State of the Union address of 2023. As previously explained 1 , the Commission appointed Mr Draghi as unpaid Special Adviser to the President of the Commission from 3 October 2023 to 30 September 2024. The Commission made available a team to support him for this specific task, composed of Commission experts in the relevant areas for the duration of the preparation of the report. In its conclusions of 29-30 June 2023, the European Council called for an independent HighLevel Report on the future of the Single Market to be presented at its meeting of March 2024, and invited the incoming presidencies of the Council and the Commission to take this work forward, in consultation with the Member States 2 . In response to that, the Belgian government, the Spanish government and the Commission have asked Mr Letta to write this report 3 . For this report, Mr Letta did not receive any remuneration by the Commission. 1 See response to parliamentary question E-003621/2023. 2 See European Council meeting (29 and 30 June 2023) – Conclusions, EUCO 7/23. 3 See also the Commission’s press release of 15 September 2023, IP/23/4495.”
  Accounting and auditing of EU budget
• “Mr. president, Commissioner, ladies and gentlemen. I can wholeheartedly support this report, and I'd like to thank Mr. Oliveira for his excellent work. Poverty is a violation of human rights and international law. Economic, social and cultural rights should be universal. They are indivisible and dependent upon one another. Social exclusion. Exclusion and poverty are the visible effects of an unfair and unjust distribution of wealth. However, the EU strategy will remain entirely theoretical if the rich continue to get poorer and the poorer continue to get poorer in our union. When we talk about combating poverty in Europe, it seems that we we just want to throw away money for an arms race. We are damaging the future of our children rather than finding a solution. Instead, we are becoming part of the problem. Thank you very much.”
  EU expenditure on social policy
• “President, Commissioner, ladies and gentlemen. The ambition of the Commission is exemplary. The goal is clear. But if you read through it, you have. There are serious questions. It's all very theory. And apparently not penned by people who are at home in the medical sector. How will the plans be implemented and be properly put into into action if the member states can't properly supply their own populations with medicines so that people have unlimited access to medical care? But there are clear tasks for the EU. Illnesses don't know national borders, so medical research must be cross-border. Our dependence from pharma production products from Asia must be overcome. The EU can show its strength if we stand up to the lobbyists of the big. Of Big Pharma, and to get used to conflicts with the WTO, rather than investing in rearmament, we could put the money into winning over most types of cancer and also erase the scourge of war from Europe's map. Thank you.”
  Pharmaceutical imports & exports rules